Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Seiichiro Kusuhara

Evaluation of Osimertinib Efficacy According to Body Surface Area and Body Mass Index in Patients With Non-Small Cell Lung Cancer Harboring an EGFR Mutation: A Prospective Observational Study

Thoracic Cancer

English

Prognostic Significance of IMMT Expression in Surgically‐resected Lung Adenocarcinoma

English

Related publications

Severe Hepatotoxicity Due to Osimertinib After Nivolumab Therapy in Patients With Non‐small Cell Lung Cancer Harboring EGFR Mutation

English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

English

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

English

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

English

Clinical Outcome of Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Harboring Uncommon EGFR Mutation

English

Efficacy of Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients Undergoing Dose Reduction and Those With a Low Body Surface Area

Molecular and Clinical Oncology

Cancer Research

Oncology

2014

English

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Journal of Thoracic Oncology

English

Successful Treatment With Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient With EGFR Mutation and Meningeal Carcinomatosis

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Seiichiro Kusuhara

Evaluation of Osimertinib Efficacy According to Body Surface Area and Body Mass Index in Patients With Non-Small Cell Lung Cancer Harboring an EGFR Mutation: A Prospective Observational Study

Prognostic Significance of IMMT Expression in Surgically‐resected Lung Adenocarcinoma

Related publications

Severe Hepatotoxicity Due to Osimertinib After Nivolumab Therapy in Patients With Non‐small Cell Lung Cancer Harboring EGFR Mutation

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Clinical Outcome of Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Harboring Uncommon EGFR Mutation

Efficacy of Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients Undergoing Dose Reduction and Those With a Low Body Surface Area

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Successful Treatment With Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient With EGFR Mutation and Meningeal Carcinomatosis